Good news and bad news in biotech IPO market The market for biotech initial public offerings has rebounded this year, spurred by generalist investors who previously shunned the industry, but the party won't last long, Luke Timmerman writes. Neglected diseases will get a boost, as will regional innovation hubs, and small companies will gain negotiating leverage, but some investors will lose interest after they lose money, Timmerman writes. Xconomy (7/22)  | Stop banking and start building with GE Capital, Healthcare Financial Services At GE Capital, we're not just bankers, we're builders. Supporting the growth of life science companies, large and small, as a reliable source of financing is our mission at GE Capital, Healthcare Financial Services. With in-depth industry experience and expertise, our dedicated Life Science Finance team has provided over $1.7 billion in financing over the past 10 years. Stop just banking. And start building. Learn more. | | NIAID awards $1.4M for further development of HIV assay MBio Diagnostics landed a two-year, $1.4 million grant from the National Institute of Allergy and Infectious Diseases for the next development phase of a low-cost, point-of-care HIV antigen/antibody diagnostic test. Infectious disease specialists at the University of California, San Diego, are assisting with development. The company's pipeline includes diagnostics for tuberculosis and the hepatitis C virus. Genetic Engineering & Biotechnology News (7/22)  | Getting Ready for the Physician Payment 'Sunshine' Rule
Get expert analysis and practical guidance to comply with the Physician Payment 'Sunshine' Rule, which mandates that certain manufacturers and group purchasing organizations (GPOs) report payments made to physicians, hospitals and other health-care providers.
Determine immediate action items for compliance with the rule—11 key suggested steps are outlined. Download Now. |
 | | Industrial & Environmental | Next-generation biofuel plants are moving toward commercialization Out of 12 major next-generation biofuel projects that were expected to enter service this year, nine have either opened or are on track to meet their target opening dates. Meanwhile, two have uncertain completion dates and one is complete but may not yet be in operational mode. The plants of this class generally take longer to commission than typical chemical facilities, this article notes. BiofuelsDigest.com (7/22) | BIO Survey on FDA-Sponsor Communication During Drug Development BIO is conducting a survey to capture information about your interactions with FDA during the various stages of drug development prior to submitting an NDA/BLA. This survey is designed to assist in the implementation of the PDUFA V program on Enhancing Communication during drug development. Your feedback will be used to better understand and measure FDA's existing communication practices and to help identify best practices for communicating with sponsors, which will further inform BIO's future advocacy. Take the survey. We expect it to take 20-30 minutes. If you have any questions, please contact Charles Crain. |  | The most prepared are the most dedicated." -- Raymond Berry, American football player | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment